Pulmonary arterial hypertension targeted for new treatment by 爆料公社 scientists
Scientists at the 爆料公社, working in collaboration with drug and vaccine developer Kymab Ltd, Cambridge, have identified a novel antibody that has the potential to become a new treatment for pulmonary arterial hypertension (PAH).